Longitudinally Monitoring Prostate Cancer Bone Metastasis and Treatment Response via Circulating Extracellular Vesicles
- 1Department of GU Medical Oncology The University of Texas MD Anderson Cancer Center Houston Texas USA
- 2Department of Biostatistics The University of Texas MD Anderson Cancer Center Houston Texas USA
- 3Department of Veterinary Medicine and Surgery The University of Texas MD Anderson Cancer Center Houston Texas USA
Abstract
Lethal prostate cancer (PCa) is dominated by treatment‐refractory progression in bone. In this study, we used plasma‐derived extracellular vesicles (EVs) for monitoring the tumour and therapy‐induced changes in the bone tumour microenvironment (bone‐TME) in men with bone metastatic PCa (M1b PCa). Transcriptome analysis of differentially expressed genes in plasma EVs from patients with M1b and localized (M0) PCa, identified a ‘bone metastasis signature’ (BMS) that reflects tumour‐induced bone formation. In preclinical studies, the BMS was enriched in plasma EVs from mice inoculated with bone‐metastatic MDA PCa‐118b but not with adrenal‐metastatic MDA PCa‐250 tumours. Longitudinal monitoring of the BMS for up to 50 days showed that the levels of several genes increased prior to detectable growth of bone‐forming tumours. Real‐time monitoring of the BMS from tumour‐bearing mice treated with the bone‐targeting agent Ra‐223 showed reduction of their expression that correlated with reduction in bone formation and tumour growth. Development of resistance to Ra‐223 correlated with the induction of the BMS genes. In a cohort of PCa patients with clinically localized PCa with pathologic lymph node involvement, increases in BMS genes following hormonal therapy correlated with the subsequent development of metastasis during long term follow up. The BMS may enable longitudinal monitoring of the initiation, progression and treatment response of M1b PCa.
Related
- Extracellular vesicles in colorectal cancer: M2 polarization, bidirectional regulation of CAFs, metastasis, and treatment.
- Microfluidic Profiling of an Immune Cell‐Associated Extracellular Vesicle Signature for Active Tuberculosis Diagnosis and Treatment Monitoring
- Enterovirus A71 exploits peripheral circulating extracellular vesicles to facilitate blood-brain barrier permeability
- The actively secreted plasma extracellular vesicle troponin (ASPECT) study: circulating troponin in extracellular vesicles across cardiovascular disease cohorts
- A Circulating Extracellular Vesicle-Bound Fraction of Cardiac Troponin Discriminates Myocardial Homeostasis and Disease States.
BibTeX
@article{gentile2026longitudinally,
title = {{Longitudinally Monitoring Prostate Cancer Bone Metastasis and Treatment Response via Circulating Extracellular Vesicles}},
author = {Emanuela Gentile and Paul G. Corn and Martha Zavridou and James P. Long and Jian H. Song and Anh Hoang and Andrew W. Hahn and Eleonora Dondossola and William Norton and Sue‐Hwa Lin and Christopher J. Logothetis and Theocharis Panaretakis},
journal = {Journal of Extracellular Vesicles},
year = {2026},
month = oct,
doi = {10.1002/jev2.70364},
url = {https://doi.org/10.1002/jev2.70364},
note = {CC BY},
}
RIS
TY - JOUR
TI - Longitudinally Monitoring Prostate Cancer Bone Metastasis and Treatment Response via Circulating Extracellular Vesicles
AU - Emanuela Gentile
AU - Paul G. Corn
AU - Martha Zavridou
AU - James P. Long
AU - Jian H. Song
AU - Anh Hoang
AU - Andrew W. Hahn
AU - Eleonora Dondossola
AU - William Norton
AU - Sue‐Hwa Lin
AU - Christopher J. Logothetis
AU - Theocharis Panaretakis
PY - 2026
DA - 2026/10/26
JO - Journal of Extracellular Vesicles
DO - 10.1002/jev2.70364
UR - https://doi.org/10.1002/jev2.70364
AB - Lethal prostate cancer (PCa) is dominated by treatment‐refractory progression in bone. In this study, we used plasma‐derived extracellular vesicles (EVs) for monitoring the tumour and therapy‐induced changes in the bone tumour microenvironment (bone‐TME) in men with bone metastatic PCa (M1b PCa). Transcriptome analysis of differentially expressed genes in plasma EVs from patients with M1b and localized (M0) PCa, identified a ‘bone metastasis signature’ (BMS) that reflects tumour‐induced bone formation. In preclinical studies, the BMS was enriched in plasma EVs from mice inoculated with bone‐metastatic MDA PCa‐118b but not with adrenal‐metastatic MDA PCa‐250 tumours. Longitudinal monitoring of the BMS for up to 50 days showed that the levels of several genes increased prior to detectable growth of bone‐forming tumours. Real‐time monitoring of the BMS from tumour‐bearing mice treated with the bone‐targeting agent Ra‐223 showed reduction of their expression that correlated with reduction in bone formation and tumour growth. Development of resistance to Ra‐223 correlated with the induction of the BMS genes. In a cohort of PCa patients with clinically localized PCa with pathologic lymph node involvement, increases in BMS genes following hormonal therapy correlated with the subsequent development of metastasis during long term follow up. The BMS may enable longitudinal monitoring of the initiation, progression and treatment response of M1b PCa.
SN - 2001-3078
ER -